DERMA-SMOOTHE/FS (fluocinolone acetonide) by Eurofarma Laboratórios is corticosteroid hormone receptor agonists [moa]. First approved in 1988.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
DERMA-SMOOTHE/FS is a topical corticosteroid oil formulation containing fluocinolone acetonide, a group III potency corticosteroid that works by agonizing glucocorticoid receptors to reduce inflammation. It is indicated for inflammatory and pruritic dermatological conditions requiring topical corticosteroid therapy. The oil-based formulation provides enhanced skin penetration and moisturization for affected areas.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30), brand roles will focus on defending market share and optimizing pricing strategy rather than expansion.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
Worked on DERMA-SMOOTHE/FS at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
DERMA-SMOOTHE/FS offers limited career growth opportunity due to its LOE-approaching status and minimal linked job postings (zero identified). Professionals joining this team should expect a focus on market defense, generic mitigation, and cost management rather than brand building or innovation.